Compounds, pharmaceutical compositions, processes, benzenossulfonatos, acids, forms a and B of acid ptoluenssulf u00f4nico, forms I and II of the acid naftalendissulf u00f4nico.
The present invention provides salts of(S)-1-(1-(4-chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one as ERK inhibitor.